Bulletin
Investor Alert

23andMe Holding Co.

NAS: ME

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
23andMe Holding Co.

After Hours

 --Quotes are delayed by 20 min

Mar 24, 2023, 7:40 p.m.

ME
/zigman2/quotes/222659849/composite

$

2.24

Change

+0.01 +0.45%

Volume

Volume 60,408

Quotes are delayed by 20 min

/zigman2/quotes/222659849/composite

Previous close

$ 2.19

$ 2.23

Change

+0.04 +1.83%

Day low

Day high

$2.16

$2.24

Open

52 week low

52 week high

$2.02

$6.31

Open

Company Description

23andMe Holding Co. is consumer genetics and research company, which engages to help people access, understand, and benefit from the human genome. It provides direct access to genetic information with multiple Food and Drug Administration authorizations for genetic health risk reports. The company o...

23andMe Holding Co. is consumer genetics and research company, which engages to help people access, understand, and benefit from the human genome. It provides direct access to genetic information with multiple Food and Drug Administration authorizations for genetic health risk reports. The company operates under the Consumer and Research Services segment, and the Therapeutics segment. The firm’s research platform has generated publications on the genetic underpinnings of a range of diseases, conditions, and traits. The platform also powers the 23andMe therapeutics group, pursuing drug discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory, and cardiovascular diseases, in addition to other therapeutic areas. The company was founded by Anne E. Wojcickiin 2006 and is headquartered in South San Francisco, CA.

Valuation

Price to Sales Ratio

5.09

Price to Book Ratio

1.88

Enterprise Value to EBITDA

-2.44

Enterprise Value to Sales

1.73

Total Debt to Enterprise Value

0.09

Efficiency

Revenue/Employee

354,027.00

Income Per Employee

-283,190.00

Receivables Turnover

92.78

Total Asset Turnover

0.34

Liquidity

Current Ratio

3.88

Quick Ratio

3.81

Cash Ratio

3.62

Profitability

Gross Margin

39.28

Operating Margin

-90.02

Pretax Margin

-81.27

Net Margin

-79.99

Return on Assets

-27.12

Return on Equity

-37.58

Return on Total Capital

-36.60

Return on Invested Capital

-32.87

Capital Structure

Total Debt to Total Equity

9.43

Total Debt to Total Capital

8.61

Total Debt to Total Assets

7.49

Long-Term Debt to Equity

8.58

Long-Term Debt to Total Capital

7.84

Officers and Executives

Name Age Officer Since Title
Ms. Anne E. Wojcicki 47 2006 Chief Executive Officer & Director
Mr. Steve Lemon 58 2010 Vice President-Engineering
Dr. Joyce Tung 43 2007 Vice President-Research
Dr. L. Okey Onyejekwe 46 - VP-Consumer Clinical Operations & Medical Affairs

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
02/20/2023 Joseph Selsavage
Interim CFO 		7,321   Derivative/Non-derivative trans. at $2.87 per share. 21,011
02/20/2023 Kathy L. Hibbs
Chief Administrative Officer 		5,457   Derivative/Non-derivative trans. at $2.87 per share. 15,661
02/20/2023 Kenneth J. Hillan
Chief Therapeutics Officer 		5,457   Derivative/Non-derivative trans. at $2.87 per share. 15,661
12/05/2022 Kathy L. Hibbs
Chief Administrative Officer 		26,259   Disposition at $3.25 per share. 85,341
11/20/2022 Joseph Selsavage
Interim CFO 		10,105   Derivative/Non-derivative trans. at $2.99 per share. 30,213
11/20/2022 Kathy L. Hibbs
Chief Administrative Officer 		4,628   Derivative/Non-derivative trans. at $2.99 per share. 13,837
11/20/2022 Kenneth J. Hillan
Chief Therapeutics Officer 		4,628   Derivative/Non-derivative trans. at $2.99 per share. 13,837
11/11/2022 Richard H. Scheller
Director 		18,421   Disposition at $3.24 per share. 59,684
09/06/2022 Valerie C. Montgomery Rice
Director 		3,577   Award at $3.08 per share. 11,017
09/06/2022 Valerie C. Montgomery Rice
Director 		14,633   Award at $0 per share. 0
09/06/2022 Sandra Rae Hernández
Director 		3,251   Award at $3.08 per share. 10,013
09/06/2022 Sandra Rae Hernández
Director 		14,633   Award at $0 per share. 0
09/06/2022 Peter J. Taylor
Director 		14,633   Award at $0 per share. 0
09/06/2022 Patrick Shuao-Fong Chung
Director 		3,414   Award at $3.08 per share. 10,515
09/06/2022 Patrick Shuao-Fong Chung
Director 		14,633   Award at $0 per share. 0
09/06/2022 Roelof Frederik Botha
Director 		3,251   Award at $3.08 per share. 10,013
09/06/2022 Roelof Frederik Botha
Director 		14,633   Award at $0 per share. 0
09/06/2022 Neal Mohan
Director 		14,633   Award at $0 per share. 0
09/06/2022 Richard H. Scheller
Director 		14,633   Award at $0 per share. 0
09/01/2022 Joseph Selsavage
Interim CFO 		129,761   Award at $0 per share. 0
08/25/2022 Valerie C. Montgomery Rice
Director 		17,821   Award at $3.03 per share. 53,997
08/25/2022 Valerie C. Montgomery Rice
Director 		57,755   Award at $0 per share. 0
08/25/2022 Sandra Rae Hernández
Director 		13,201   Award at $3.03 per share. 39,999
08/25/2022 Sandra Rae Hernández
Director 		57,755   Award at $0 per share. 0
08/25/2022 Peter J. Taylor
Director 		57,755   Award at $0 per share. 0
08/25/2022 Patrick Shuao-Fong Chung
Director 		18,811   Award at $3.03 per share. 56,997
08/25/2022 Patrick Shuao-Fong Chung
Director 		57,755   Award at $0 per share. 0
08/25/2022 Roelof Frederik Botha
Director 		16,501   Award at $3.03 per share. 49,998
08/25/2022 Roelof Frederik Botha
Director 		57,755   Award at $0 per share. 0
08/25/2022 Neal Mohan
Director 		57,755   Award at $0 per share. 0
08/25/2022 Richard H. Scheller
Director 		57,755   Award at $0 per share. 0
08/24/2022 Kenneth J. Hillan
Chief Therapeutics Officer 		8,753   Disposition at $3.64 per share. 31,860
08/20/2022 Kathy L. Hibbs
Chief Administrative Officer 		4,628   Derivative/Non-derivative trans. at $3.33 per share. 15,411
08/20/2022 Steven J. Schoch
Chief Financial Officer 		4,782   Derivative/Non-derivative trans. at $3.33 per share. 15,924
08/20/2022 Kenneth J. Hillan
Chief Therapeutics Officer 		4,628   Derivative/Non-derivative trans. at $3.33 per share. 15,411
06/01/2022 Kathy L. Hibbs
Chief Administrative Officer 		4,627   Derivative/Non-derivative trans. at $2.82 per share. 13,048
06/01/2022 Steven J. Schoch
Chief Financial Officer 		4,782   Derivative/Non-derivative trans. at $2.82 per share. 13,485
06/01/2022 Kenneth J. Hillan
Chief Therapeutics Officer 		4,627   Derivative/Non-derivative trans. at $2.82 per share. 13,048
/news/latest/company/us/me

MarketWatch News on ME

  1. 23andMe stock jumps more than 12% on raised 2023 guidance

    5:50 p.m. Feb. 8, 2023

    - Claudia Assis

  2. 23andMe stock falls after company says CFO to depart

    8:43 a.m. Aug. 19, 2022

    - Emily Bary

  5. Branson reportedly eyes Amsterdam for first European SPAC

    10:07 a.m. Jan. 7, 2022

    - Steve Goldstein

  6. The S&P 500 Didn't Budge Today. But Bond Yields Popped.

    6:28 p.m. Nov. 15, 2021

    - Barron's Online

  7. 23andMe buys telemedicine specialist Lemonaid Health

    7:20 a.m. Oct. 22, 2021

    - Steve Gelsi

  13. Dow Sees Worst Week In 8 Months. Inflation Trade Sputters.

    4:56 p.m. June 18, 2021

    - Barron's Online

  19. These 3 Firms Could Be the Next SPAC Targets

    3:39 p.m. Feb. 5, 2021

    - Barron's Online

  21. Loading more headlines...
/news/nonmarketwatch/company/us/me

Other News on ME

  1. WSJ. Magazine Celebrates Style & Tech in Silicon Valley

    2:33 p.m. March 21, 2023

    - The Wall Street Journal Interactive Edition

  2. How DNA Tied a Noted French-Horn Teacher to a String of Unsolved Sex Crimes

    3:34 a.m. Feb. 23, 2023

    - The Wall Street Journal Interactive Edition

  3. Top 5 4th Quarter Trades of ALLEN OPERATIONS LLC

    1:00 a.m. Feb. 15, 2023

    - GuruFocus.com

  4. Top 5 4th Quarter Trades of Liberty Street Advisors, Inc.

    3:00 p.m. Feb. 3, 2023

    - GuruFocus.com

  5. Misleading Ads Fueled Rapid Growth of Online Mental Health Companies

    3:56 p.m. Dec. 28, 2022

    - The Wall Street Journal Interactive Edition

  6. CareDx: Organ Transplant Business Falters In Q3

    3:40 p.m. Nov. 11, 2022

    - Seeking Alpha

  7. 23andMe Holding Co. (ME) Q2 2023 Earnings Call Transcript

    11:32 p.m. Nov. 7, 2022

    - Seeking Alpha

  8. 10-Q: 23ANDME HOLDING CO.

    5:17 p.m. Nov. 7, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  9. 23andMe GAAP EPS of -$0.15, revenue of $75.66M

    5:12 p.m. Nov. 7, 2022

    - Seeking Alpha

  10. Check on Your FSA Now, or Be Stuck Buying Sunscreen in December

    7:30 a.m. Nov. 4, 2022

    - The Wall Street Journal Interactive Edition

  11. Liberty Street Advisors, Inc. Buys 1, Sells 4 in 3rd Quarter

    5:00 p.m. Nov. 2, 2022

    - GuruFocus.com

  14. 2 Ex-SPACs I Wouldn't Touch Right Now

    6:22 a.m. Sept. 2, 2022

    - Motley Fool

  16. 23andMe: Treacherous Path To Profitability

    6:17 p.m. Aug. 26, 2022

    - Seeking Alpha

  17. News From Walmart and Other Members of Big Retail

    2:24 p.m. Aug. 22, 2022

    - Motley Fool

  18. 23andMe drops 8% as CFO resigns

    9:32 a.m. Aug. 19, 2022

    - Seeking Alpha

  21. Loading more headlines...

At a Glance

23andMe Holding Co.

349 Oyster Point Boulevard

South San Francisco, California 94080

Phone

1 6509386300

Industry

-

Sector

-

Fiscal Year-end

03/2023

View SEC Filings

Revenue

$271.89M

Net Income

$-217.49M

2022 Sales Growth

11.5%

Employees

768.00

Annual Report for ME

/news/pressrelease/company/us/me

Press Releases on ME

  6. 23andMe to Present at Upcoming Investor Conferences

    5:05 p.m. Feb. 22, 2023

    - GlobeNewswire

  8. 23andMe Reports FY2023 Third Quarter Financial Results

    5:05 p.m. Feb. 8, 2023

    - GlobeNewswire

  9. 23andMe to Report FY2023 Third Quarter Financial Results

    5:05 p.m. Jan. 26, 2023

    - GlobeNewswire

  11. Moneta Provides 2022 Year-End Review & 2023 Plans

    7:52 a.m. Jan. 6, 2023

    - Newsfile Corp

  13. Moneta Welcomes Sheila Colman to its Board of Directors

    1:14 p.m. Dec. 14, 2022

    - Newsfile Corp

  19. The NIH Has Given BioRestorative Therapies A Stamp Of Approval

    9:02 a.m. Nov. 10, 2022

    - TheNewswire.ca

  21. Loading more headlines...
Link to MarketWatch's Slice.